Veracyte Inc (FRA:12V)
€ 32 0.6 (1.91%) Market Cap: 2.54 Bil Enterprise Value: 2.34 Bil PE Ratio: 0 PB Ratio: 2.37 GF Score: 83/100

Veracyte Inc at Needham Healthcare Conference Transcript

Apr 10, 2019 / 12:00PM GMT
Release Date Price: €22.07 (-0.45%)
Stephen Scott Unger
Needham & Company, LLC, Research Division - Senior Analyst

Hi, everyone. In the interest of time, I'll get us started this morning. Thank you, everyone, for joining us. This is the second day of the Needham 18th Annual Healthcare Conference. My name is Steve Unger. I'm the life science tools and diagnostics analyst here at Needham, and it is certainly my pleasure to introduce our first company today in our cancer diagnostics track. This is Veracyte. Ticker is VCYX and -- VCYT, sorry, sorry.

And with us today is Bonnie Anderson, Chairman and CEO; Keith Kennedy, Chief Financial Officer; and Angie McCabe, Director of Investor Relations. Bonnie is going to provide a quick -- an overview of the company, and if there's time available, we'll open it up for some questions in the room.

And with that, I'm going to hand it over to Bonnie.

Bonnie H. Anderson
Veracyte, Inc. - Co-Founder, Chairman & CEO

Thank you, Steve. I'd like to start by thanking Needham for inviting us to present at the conference this year, and it's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot